Lymphosarcoma is the old name and the current name is lymphoma. Lymphosarcoma includes two major types of Hodgkin’s lymphoma malignant non-Hodgkin’s lymphoma, which are treated mainly according to different staging. A portion of lymphosarcomas are more sensitive to chemotherapy and radiotherapy regimens and have better results. Some can also be targeted with monoclonal antibodies, for example, B-cell type non-Hodgkin’s lymphoma has an antibody against CD20, rituximab, which is also very effective. t cells may not have a clear target therapeutic antibody. A more precise treatment for lymphosarcoma should be based on its staging and certain radiotherapy and chemotherapy depending on its location. The real staging of lymphosarcoma, whether it is systemic or not, may be referred to the hematology department for a bone marrow aspiration and PET-CT examination to evaluate the staging and staging, and finally decide on a more precise treatment plan for a better chance of cure.